Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy

Aim:  Hepatic steatosis is one of the factors limiting the virological response to interferon‐based antiviral therapy for chronic hepatitis C (CH‐C) patients infected with genotype 1, while contradictory results have been reported for genotype 2. We aimed to clarify the effect of hepatic steatosis on therapeutic outcome and cumulative positivity of serum HCV RNA in CH‐C patients infected with genotype 2 treated by peginterferon (PEG‐IFN)α2b and ribavirin (RBV) combination therapy.

[1]  M. Kurosaki,et al.  Association of IL28B variants with response to pegylated‐interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b , 2011, Journal of medical virology.

[2]  N. Enomoto,et al.  Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. , 2011, Journal of hepatology.

[3]  Yusuke Nakamura,et al.  Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. , 2011, Journal of hepatology.

[4]  Y. Imai,et al.  Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha‐2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses , 2010, Journal of viral hepatitis.

[5]  J. Pawlotsky,et al.  Hepatitis C Virus Proteins Induce Lipogenesis and Defective Triglyceride Secretion in Transgenic Mice* , 2009, The Journal of Biological Chemistry.

[6]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[7]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[8]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[9]  G. Marchesini,et al.  Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C , 2009, Hepatology.

[10]  K. Eguchi,et al.  Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  A. Andriulli,et al.  Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection , 2009, Hepatology.

[12]  M. Shiffman,et al.  Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α‐2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[13]  C. Ríos-Bedoya,et al.  Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa‐2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks , 2008, Journal of medical virology.

[14]  G. Norkrans,et al.  Randomized comparison of 12 or 24 weeks of peginterferon α‐2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection , 2008, Hepatology.

[15]  A. Mangia,et al.  Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus , 2008, Journal of medical economics.

[16]  E. Bjornsson,et al.  Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response , 2007, Hepatology.

[17]  H. Tillmann.  Does the presence of hepatic steatosis influence the efficacy of antiviral treatment in patients with hepatitis C? , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[18]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[19]  William M. Lee,et al.  Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  Ming‐Lung Yu,et al.  A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C , 2006, Gut.

[21]  T. Asselah,et al.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. , 2006, Gastroenterology.

[22]  T. Berg,et al.  Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C , 2005 .

[23]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[24]  Yoshiyuki Suzuki,et al.  Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis , 2005, Journal of medical virology.

[25]  J. McHutchison,et al.  The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. , 2004, Journal of hepatology.

[26]  M. Manns,et al.  Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C , 2003, Hepatology.

[27]  Yoshiyuki Suzuki,et al.  Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. , 2002, Journal of hepatology.

[28]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[29]  Takao Tsuji,et al.  New Inuyama classification; new criteria for histological assessment of chronic hepatitis , 1996 .

[30]  J. Kench,et al.  Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. , 2008, Journal of hepatology.

[31]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .